Coherus BioSciences 2024年第四季度调整后每股亏损$(0.28),不及预期$(0.13),销售额$5414.4万超过预期$4727.0万

财报速递2025-03-11
Coherus BioSciences (NASDAQ:CHRS) 报告季度每股亏损$(0.28),低于分析师一致预期的$(0.13),减少了115.38%。与去年同期每股亏损$(0.62)相比,这是一个54.84%的改善。公司报告季度销售额为$5414.4万,超过分析师一致预期的$4727.0万,高出14.54%。与去年同期$9152.4万相比,这减少了40.84%。

以上内容来自Benzinga Earnings专栏,原文如下:

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.13) by 115.38 percent. This is a 54.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million by 14.54 percent. This is a 40.84 percent decrease over sales of $91.524 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法